Matrix metalloproteinase-1, Matrix metalloproteinase-2, and Matrix metalloproteinase-9 (MMP-1/2/9)

Matrix metalloproteinase-1 (MMP-1), Matrix metalloproteinase-2 (MMP-2), and Matrix metalloproteinase-9 (MMP-9) are zinc-dependent endopeptidases that play fundamental roles in the degradation and remodeling of the extracellular matrix (ECM) [1, 6]. MMP-1, or interstitial collagenase, primarily cleaves fibrillar collagens, while MMP-2 and MMP-9, known as gelatinases, degrade type IV collagen and gelatin, which are major components of the basement membrane [3, 5]. These enzymes are essential for physiological processes such as wound healing, angiogenesis, and embryogenesis, but their dysregulation is a hallmark of various pathologies, including cancer metastasis, rheumatoid arthritis, and cardiovascular disease [2, 4, 10]. In oncology, they facilitate tumor invasion by breaking down physical barriers and releasing sequestered growth factors like VEGF [8, 13]. Beyond structural roles, they modulate the activity of cytokines and chemokines, thereby regulating inflammatory responses [9, 15]. Although they are significant therapeutic targets, the clinical development of broad-spectrum MMP inhibitors has been hindered by severe side effects, most notably musculoskeletal syndrome (MSS), and a lack of selectivity between family members [2, 11]. Current research focuses on developing highly selective small molecules or monoclonal antibodies, such as andecaliximab, to target specific MMPs while minimizing off-target toxicity [7, 14]. These enzymes also serve as important biomarkers; for instance, elevated MMP-9 levels in serum or urine are associated with poor prognosis in several cancers and cardiovascular events [8, 10].

Other names

Interstitial collagenaseGelatinase AGelatinase B72 kDa type IV collagenase92 kDa type IV collagenaseMatrix metallopeptidase 1Matrix metallopeptidase 2Matrix metallopeptidase 9MatrixinsMMP1MMP2MMP9

Inhibition of the zinc-dependent catalytic domain through chelation or allosteric binding, and neutralization via monoclonal antibodies [2, 6, 14].